ReNAgade Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $1.2B
Overview
An integrated RNA delivery platform company aiming to treat genetic diseases across multiple tissues.
Genetic DiseasesNeurology
Technology Platform
Develops an integrated platform combining novel lipid nanoparticle delivery technology with multiple RNA modalities (mRNA, RNAi, gene editing) for extrahepatic targeting.
Funding History
4Total raised:$1.2B
Series D$300M
Series C$300M
Series B$300M
Series A$300M
Opportunities
Successfully delivering RNA therapeutics beyond the liver would open vast, untapped markets for treating genetic CNS and pulmonary diseases.
Risk Factors
High technical risk associated with proving its novel delivery technology is safe and effective in humans.
Competitive Landscape
Faces competition from numerous biotechs and large pharma companies also developing next-generation RNA delivery and editing platforms.